Granahan Investment Management LLC Acquires New Stake in Immunome, Inc. (NASDAQ:IMNM)

Granahan Investment Management LLC purchased a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 314,239 shares of the company's stock, valued at approximately $3,337,000. Granahan Investment Management LLC owned 0.39% of Immunome at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of IMNM. Charles Schwab Investment Management Inc. grew its position in shares of Immunome by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock worth $4,856,000 after buying an additional 14,775 shares during the last quarter. Magnus Financial Group LLC grew its position in shares of Immunome by 107.8% in the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares during the last quarter. Scharf Investments LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $471,000. Three Bridge Wealth Advisors LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $293,000. Finally, Barclays PLC grew its position in shares of Immunome by 125.9% in the 3rd quarter. Barclays PLC now owns 105,886 shares of the company's stock worth $1,547,000 after buying an additional 59,016 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on IMNM shares. Lake Street Capital started coverage on Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target on the stock. Guggenheim dropped their price target on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Wedbush reissued an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a report on Tuesday. Lifesci Capital began coverage on Immunome in a report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 target price on the stock. Finally, Stephens reissued an "overweight" rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $23.33.

Immunome Trading Up 0.8%

Immunome stock traded up $0.06 during mid-day trading on Wednesday, hitting $7.97. The company had a trading volume of 915,117 shares, compared to its average volume of 917,765. The stock's 50 day moving average price is $7.71 and its two-hundred day moving average price is $9.90. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81. The company has a market capitalization of $693.49 million, a PE ratio of -0.98 and a beta of 2.00.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. Equities research analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 137,100 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was acquired at an average price of $8.21 per share, with a total value of $57,470.00. Following the purchase, the director now directly owns 23,615 shares of the company's stock, valued at approximately $193,879.15. The trade was a 42.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 156,400 shares of company stock worth $1,160,495 over the last quarter. 8.60% of the stock is currently owned by insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.